Anzeige
Erschienen in:
01.02.2016 | Erratum
Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option
Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2016
Einloggen, um Zugang zu erhaltenExcerpt
Figure 1c in the original publication had nuclear lamin B controls inserted in both the cytoplasm and nucleus sets. The revised Fig. 1c show the correct GAPDH controls. The authors regret this error.
Fig. 1
a Proposed hypothesis: Small molecule inhibitors of BRCT(BRCA1)–phosphoprotein interaction will increase the sensitivity of cancer cells to DNA damage based therapeutics. The inhibitor is represented as a red X. b Competitive inhibition curves for BRCT(BRCA1) inhibitor peptides 1 (Ac-pSPTF-CO2H) and 2 (Ac-R10 G-pSPTF-CO2H). c IP and IB studies with and without the BRCT inhibitor 2 in the presence and absence of IR-induced DNA damage
× ![]()
…